{
    "nct_id": "NCT05685004",
    "official_title": "Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)",
    "inclusion_criteria": "* Newly diagnosed MGMT unmethylated glioblastoma multiforme (no prior treatment)\n* Sufficient cancer tissue obtained to allow for manufacture of autologous cancer cell vaccines\n* The attenuated autologous cancer cell product generated has satisfied the product release criteria as determined by the sponsor quality control department\n* Medical history, physical examination and laboratory testing performed within approximately 7 days before enrollment revealing kidney and liver organ function within normal limits\n* not currently receiving glucocorticoids and have been off glucocorticoids for at least 24 hours prior to vaccination as well as when they receive the T cell infusion.\n* Patient function assessment (Karnofsky score is > 60)\n* a life expectancy of > 12 weeks.\n* Hemoglobin is > 10 g/dL (may be transfused)\n* White blood cell count is > 3,000 cells/microliter (mcL) of blood.\n* Platelet count is > 100,000 platelets per mcL of blood (transfusion independent)\n* Lymphocyte count is > 1,000 cells/mcL of blood.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* another concomitant life-threatening disease (not including glioblastoma multiforme)\n* a second malignancy that is not in remission as determined by the clinical investigator. Exception: squamous or basal cell carcinoma of the skin.\n* requirement for treatment with glucocorticoids to control brain swelling\n* presence of active autoimmune disease that is currently being actively treated.\n* psychological, familial, sociological or geographical conditions that do not permit adequate medical follow-up and compliance with the study protocol.\n* Current pregnancy or a plan to become pregnant within 1-year following the study.",
    "miscellaneous_criteria": ""
}